Illumina, Inc. (0J8Z.L)
USD 137.9
(-3.76%)
USD 137.9
(-3.76%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 2.26 Billion USD | -34.98% |
| 2022 | 3.47 Billion USD | 40.91% |
| 2021 | 2.46 Billion USD | 33.1% |
| 2020 | 1.85 Billion USD | 1.03% |
| 2019 | 1.83 Billion USD | -8.06% |
| 2018 | 1.99 Billion USD | 49.48% |
| 2017 | 1.33 Billion USD | 5.05% |
| 2016 | 1.27 Billion USD | 16.62% |
| 2015 | 1.09 Billion USD | -15.53% |
| 2014 | 1.29 Billion USD | 48.64% |
| 2013 | 868.59 Million USD | 3.11% |
| 2012 | 842.37 Million USD | 4.34% |
| 2011 | 807.36 Million USD | 159.1% |
| 2010 | 311.6 Million USD | 7.38% |
| 2009 | 290.2 Million USD | -27.45% |
| 2008 | 399.99 Million USD | -0.0% |
| 2007 | 400.01 Million USD | 634846.03% |
| 2006 | 63 Thousand USD | -63.37% |
| 2005 | 172 Thousand USD | 0.0% |
| 2004 | - USD | -100.0% |
| 2003 | 25.61 Million USD | -2.58% |
| 2002 | 26.29 Million USD | 2864.71% |
| 2001 | 887 Thousand USD | -22.7% |
| 2000 | 1.14 Million USD | 76399.6% |
| 1999 | 1500.00 USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 2.27 Billion USD | 0.62% |
| 2024 Q3 | 2.6 Billion USD | -8.46% |
| 2024 Q2 | 2.92 Billion USD | 28.34% |
| 2023 Q4 | 2.26 Billion USD | 3.43% |
| 2023 Q3 | 2.18 Billion USD | -26.21% |
| 2023 FY | 2.26 Billion USD | -34.98% |
| 2023 Q1 | 2.98 Billion USD | -14.26% |
| 2023 Q2 | 2.96 Billion USD | -0.64% |
| 2022 Q3 | 2.48 Billion USD | -3.9% |
| 2022 Q4 | 3.47 Billion USD | 39.78% |
| 2022 FY | 3.47 Billion USD | 40.91% |
| 2022 Q1 | 2.61 Billion USD | 5.91% |
| 2022 Q2 | 2.59 Billion USD | -0.96% |
| 2021 Q2 | 2.38 Billion USD | -15.62% |
| 2021 FY | 2.46 Billion USD | 33.1% |
| 2021 Q1 | 2.82 Billion USD | 52.24% |
| 2021 Q4 | 2.46 Billion USD | -0.08% |
| 2021 Q3 | 2.47 Billion USD | 3.69% |
| 2020 FY | 1.85 Billion USD | 1.03% |
| 2020 Q1 | 1.84 Billion USD | 0.6% |
| 2020 Q2 | 1.84 Billion USD | -0.22% |
| 2020 Q4 | 1.85 Billion USD | 0.22% |
| 2020 Q3 | 1.85 Billion USD | 0.43% |
| 2019 Q4 | 1.83 Billion USD | 0.77% |
| 2019 FY | 1.83 Billion USD | -8.06% |
| 2019 Q3 | 1.82 Billion USD | 0.22% |
| 2019 Q1 | 2.46 Billion USD | 23.23% |
| 2019 Q2 | 1.81 Billion USD | -26.13% |
| 2018 FY | 1.99 Billion USD | 49.48% |
| 2018 Q1 | 1.35 Billion USD | 1.12% |
| 2018 Q2 | 1.36 Billion USD | 1.33% |
| 2018 Q3 | 1.98 Billion USD | 45.29% |
| 2018 Q4 | 1.99 Billion USD | 0.4% |
| 2017 Q1 | 1.24 Billion USD | -1.87% |
| 2017 Q4 | 1.33 Billion USD | 2.3% |
| 2017 Q3 | 1.3 Billion USD | 0.62% |
| 2017 Q2 | 1.29 Billion USD | 4.01% |
| 2017 FY | 1.33 Billion USD | 5.05% |
| 2016 FY | 1.27 Billion USD | 16.62% |
| 2016 Q4 | 1.27 Billion USD | 4.22% |
| 2016 Q3 | 1.22 Billion USD | 18.26% |
| 2016 Q2 | 1.03 Billion USD | 0.9% |
| 2016 Q1 | 1.02 Billion USD | -6.23% |
| 2015 Q1 | 1.3 Billion USD | 0.79% |
| 2015 FY | 1.09 Billion USD | -15.53% |
| 2015 Q2 | 1.3 Billion USD | 0.16% |
| 2015 Q4 | 1.09 Billion USD | -1.76% |
| 2015 Q3 | 1.11 Billion USD | -14.82% |
| 2014 Q3 | 1.28 Billion USD | 0.79% |
| 2014 FY | 1.29 Billion USD | 48.64% |
| 2014 Q4 | 1.29 Billion USD | 0.79% |
| 2014 Q2 | 1.27 Billion USD | 49.87% |
| 2014 Q1 | 848.01 Million USD | -2.37% |
| 2013 FY | 868.59 Million USD | 3.11% |
| 2013 Q4 | 868.59 Million USD | 1.06% |
| 2013 Q1 | 860.74 Million USD | 2.18% |
| 2013 Q2 | 851.9 Million USD | -1.03% |
| 2013 Q3 | 859.5 Million USD | 0.89% |
| 2012 FY | 842.37 Million USD | 4.34% |
| 2012 Q1 | 815.96 Million USD | 1.07% |
| 2012 Q3 | 833.46 Million USD | 1.07% |
| 2012 Q4 | 842.37 Million USD | 1.07% |
| 2012 Q2 | 824.66 Million USD | 1.07% |
| 2011 Q3 | 798.87 Million USD | 0.12% |
| 2011 FY | 807.36 Million USD | 159.1% |
| 2011 Q4 | 807.36 Million USD | 1.06% |
| 2011 Q2 | 797.92 Million USD | 4.52% |
| 2011 Q1 | 763.4 Million USD | 144.99% |
| 2010 Q4 | 311.6 Million USD | 1.8% |
| 2010 FY | 311.6 Million USD | 7.38% |
| 2010 Q3 | 306.1 Million USD | 1.8% |
| 2010 Q1 | 295.4 Million USD | 1.79% |
| 2010 Q2 | 300.7 Million USD | 1.79% |
| 2009 Q4 | 290.2 Million USD | 1.93% |
| 2009 FY | 290.2 Million USD | -27.45% |
| 2009 Q1 | 274.79 Million USD | -31.3% |
| 2009 Q2 | 279.7 Million USD | 1.79% |
| 2009 Q3 | 284.7 Million USD | 1.79% |
| 2008 Q1 | 400 Million USD | -0.0% |
| 2008 Q3 | 400.58 Million USD | -3.45% |
| 2008 Q4 | 399.99 Million USD | -0.15% |
| 2008 FY | 399.99 Million USD | -0.0% |
| 2008 Q2 | 414.88 Million USD | 3.72% |
| 2007 Q3 | 400.02 Million USD | -0.0% |
| 2007 Q1 | 400.07 Million USD | 634936.51% |
| 2007 FY | 400.01 Million USD | 634846.03% |
| 2007 Q2 | 400.04 Million USD | -0.01% |
| 2007 Q4 | 400.01 Million USD | -0.0% |
| 2006 FY | 63 Thousand USD | -63.37% |
| 2006 Q2 | 114 Thousand USD | -20.28% |
| 2006 Q1 | 143 Thousand USD | -16.86% |
| 2006 Q3 | 94 Thousand USD | -17.54% |
| 2006 Q4 | 63 Thousand USD | -32.98% |
| 2005 Q2 | - USD | 0.0% |
| 2005 FY | 172 Thousand USD | 0.0% |
| 2005 Q4 | 172 Thousand USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2004 FY | - USD | -100.0% |
| 2004 Q3 | - USD | -100.0% |
| 2004 Q2 | 25.18 Million USD | -1.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 Q1 | 25.43 Million USD | -0.71% |
| 2003 Q3 | 25.78 Million USD | -0.65% |
| 2003 Q4 | 25.61 Million USD | -0.66% |
| 2003 FY | 25.61 Million USD | -2.58% |
| 2003 Q1 | 25.96 Million USD | -1.26% |
| 2003 Q2 | 25.95 Million USD | -0.03% |
| 2002 FY | 26.29 Million USD | 2864.71% |
| 2002 Q1 | 26.24 Million USD | 2858.74% |
| 2002 Q2 | 26.17 Million USD | -0.26% |
| 2002 Q3 | 26.11 Million USD | -0.24% |
| 2002 Q4 | 26.29 Million USD | 0.71% |
| 2001 Q1 | 1.08 Million USD | -5.41% |
| 2001 Q2 | 1.02 Million USD | -5.91% |
| 2001 Q4 | 887 Thousand USD | -7.12% |
| 2001 Q3 | 955.01 Thousand USD | -6.49% |
| 2001 FY | 887 Thousand USD | -22.7% |
| 2000 Q2 | 1.26 Million USD | 0.0% |
| 2000 Q4 | 1.14 Million USD | -4.98% |
| 2000 Q1 | - USD | 0.0% |
| 2000 Q3 | 1.2 Million USD | -4.6% |
| 2000 FY | 1.14 Million USD | 76399.6% |
| 1999 FY | 1500.00 USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | 36.53 Million USD | -6091.154% |
| Dynavax Technologies Corporation | 256.91 Million USD | -780.45% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | -5347.059% |
| Perrigo Company plc | 4.07 Billion USD | 44.469% |
| Thermo Fisher Scientific Inc. | 34.91 Billion USD | 93.522% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -226100.0% |
| Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 76.324% |
| IQVIA Holdings Inc. | 14.23 Billion USD | 84.105% |
| Heron Therapeutics, Inc. | 173.75 Million USD | -1201.848% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 16.312% |
| Unity Biotechnology, Inc. | 26.99 Million USD | -8280.882% |
| Waters Corporation | 2.35 Billion USD | 3.97% |
| Biogen Inc. | 7.33 Billion USD | 69.175% |
| Sangamo Therapeutics, Inc. | 38.1 Million USD | -5836.385% |
| Evolus, Inc. | 126.54 Million USD | -1687.492% |
| Adicet Bio, Inc. | 17.7 Million USD | -12677.495% |
| Cara Therapeutics, Inc. | 43.16 Million USD | -5140.114% |
| bluebird bio, Inc. | 330.32 Million USD | -584.778% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | -318.156% |
| FibroGen, Inc. | 170.45 Million USD | -1227.036% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 17.294% |
| Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | -10731.138% |
| Homology Medicines, Inc. | 44.05 Million USD | -5034.608% |
| Geron Corporation | 85.89 Million USD | -2533.325% |
| Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | 5.672% |
| Amicus Therapeutics, Inc. | 445.05 Million USD | -408.247% |
| Myriad Genetics, Inc. | 145 Million USD | -1460.0% |
| Viking Therapeutics, Inc. | 1.26 Million USD | -179423.81% |
| Intellia Therapeutics, Inc. | 115.34 Million USD | -1861.056% |
| Zoetis Inc. | 6.8 Billion USD | 66.75% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -51285.734% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | -4.347% |
| BioMarin Pharmaceutical Inc. | 1.13 Billion USD | -99.493% |
| Vertex Pharmaceuticals Incorporated | 808.4 Million USD | -179.812% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | -6127.459% |
| Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | -55.62% |
| Atara Biotherapeutics, Inc. | 57.87 Million USD | -3808.626% |
| Verastem, Inc. | 41.55 Million USD | -5343.126% |
| Nektar Therapeutics | 230.4 Million USD | -881.767% |
| Axsome Therapeutics, Inc. | 186.37 Million USD | -1113.702% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -73484.906% |
| Sarepta Therapeutics, Inc. | 1.39 Billion USD | -61.941% |
| OPKO Health, Inc. | 326.56 Million USD | -592.667% |
| Exelixis, Inc. | 189.94 Million USD | -1090.877% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | -428.011% |
| Corcept Therapeutics Incorporated | 151 Thousand USD | -1497913.245% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 138.4 Million USD | -1534.287% |
| Imunon, Inc. | 1.13 Million USD | -198444.185% |
| Blueprint Medicines Corporation | 774.12 Million USD | -192.202% |
| Insmed Incorporated | 1.2 Billion USD | -87.875% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | -50.876% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -3869.257% |
| TG Therapeutics, Inc. | 110.79 Million USD | -1941.608% |
| Incyte Corporation | 38.28 Million USD | -5808.011% |
| Emergent BioSolutions Inc. | 877.5 Million USD | -157.778% |